Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tenaya Therapeutics Inc TNYA

Healthcare Biotechnology
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s... see more

Recent & Breaking News (NDAQ:TNYA)

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

GlobeNewswire April 21, 2023

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 8, 2023

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire February 7, 2023

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

GlobeNewswire January 9, 2023

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

GlobeNewswire December 7, 2022

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

GlobeNewswire November 28, 2022

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

GlobeNewswire November 23, 2022

Tenaya Therapeutics Announces Closing of Public Offering

GlobeNewswire November 21, 2022

Tenaya Therapeutics Announces Pricing of Public Offering

GlobeNewswire November 17, 2022

Tenaya Therapeutics Announces Proposed Public Offering

GlobeNewswire November 16, 2022

Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 10, 2022

Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022

GlobeNewswire November 4, 2022

Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress

GlobeNewswire October 4, 2022

Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society's 2022 Scientific Sessions

GlobeNewswire September 29, 2022

Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences

GlobeNewswire September 29, 2022

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire September 6, 2022

Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction

GlobeNewswire September 6, 2022

Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 10, 2022

Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure

GlobeNewswire July 6, 2022

Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics

Business Wire June 16, 2022